<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182245</url>
  </required_header>
  <id_info>
    <org_study_id>1199.6</org_study_id>
    <nct_id>NCT02182245</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies</brief_title>
  <official_title>A Phase I Open Label Dose Escalation Study of Oral Treatment With BIBF 1120 in Combination With Standard Treatment of Paclitaxel and Carboplatin in Patients With Advanced Gynaecological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objectives of this trial were to determine the safety, tolerability, and MTD of&#xD;
      BIBF 1120 when added to standard therapy with carboplatin and paclitaxel&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of BIBF 1120</measure>
    <time_frame>up to 126 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and intensity of adverse events according to the CTCAE (Common terminology criteria for adverse events Version) version 3.0 with increasing doses of BIBF 1120</measure>
    <time_frame>up to 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumour response after treatment with BIBF 1120 in combination with carboplatin and paclitaxel in evaluable patients</measure>
    <time_frame>up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer antigen 125 (CA-125) response</measure>
    <time_frame>Day 1 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumour progression (time from treatment start to the time of documented tumour progression)</measure>
    <time_frame>up to 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Genital Neoplasms, Female</condition>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120</intervention_name>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients with the following histologically confirmed advanced gynaecological&#xD;
             malignancies: epithelial ovarian cancer, endometrial carcinoma, uterine sarcoma, mixed&#xD;
             Müllerian tumour, fallopian tube carcinoma, primary peritoneal carcinoma, cervical&#xD;
             carcinoma or vulvular carcinoma&#xD;
&#xD;
          -  Metastatic disease or locally advanced disease that is not resectable with curative&#xD;
             intention&#xD;
&#xD;
          -  Indication for combination chemotherapy with paclitaxel/carboplatin as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 6 months&#xD;
&#xD;
          -  Written informed consent that is not consistent with ICH-GCP (International Conference&#xD;
             on Harmonisation - Good Clinical Practice) guidelines and local requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical study within the past 4 weeks before start of&#xD;
             therapy or concomitantly with this study&#xD;
&#xD;
          -  Radiotherapy within 4 weeks before the start of therapy&#xD;
&#xD;
          -  Chemotherapy, immunotherapy or hormonal therapy (with the exception of hormonal&#xD;
             replacement therapy) within 4 weeks before the start of the therapy&#xD;
&#xD;
          -  Patients with germ cell tumours, early stage ovarian cancer (Fédération Internationale&#xD;
             de Gynécologie et d'Obstétrique [FIGO] stage I-IIA), primary cervical cancer (FIGO&#xD;
             I-III), primary endometrial cancer (FIGO I-III) or borderline tumours&#xD;
&#xD;
          -  Patients with known brain metastases&#xD;
&#xD;
          -  Symptomatic bowel obstruction or known or suspected malabsorption&#xD;
&#xD;
          -  Patients with pericardial effusion which is haemodynamically relevant&#xD;
&#xD;
          -  Other malignancy diagnosed within the past 5 years (other than non-melanomatous skin&#xD;
             cancer or cervical carcinoma in situ)&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study medication&#xD;
&#xD;
          -  History of haemorrhagic or thrombotic event (including transient ischemic attacks) in&#xD;
             the past 6 months&#xD;
&#xD;
          -  Concurrent therapeutic anticoagulation or anti-platelet therapy (except chronic low&#xD;
             dose daily acetylsalicylic acid &lt;300 mg)&#xD;
&#xD;
          -  Major injuries and surgeries within the past 3 weeks, planned surgical procedures&#xD;
             during the trial, incomplete wound healing&#xD;
&#xD;
          -  Known hypersensitivity to paclitaxel, carboplatin, BIBF 1120 or any of their&#xD;
             excipients or vehicles such as polyoxyethylated castor oil&#xD;
&#xD;
          -  Clinically significant peripheral polyneuropathy (&gt;CTCAE grade 1) which precludes&#xD;
             therapy with paclitaxel&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt;1500/μL, platelet count &lt;100000/μL, or haemoglobin &lt;9&#xD;
             mg/dL&#xD;
&#xD;
          -  Total bilirubin &gt;1.5 mg/dL (26 μmol/L), ALT (Alanine aminotransferase) and/or AST&#xD;
             (Aspartate aminotransferase) &gt;1.5 x the upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 mg/dL (&gt;132 μmol/L)&#xD;
&#xD;
          -  Persistent gross haematuria&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Women with childbearing potential and who are sexually active and unwilling to use a&#xD;
             medically acceptable method of contraception (oral contraceptive, diaphragm with&#xD;
             spermicide, intrauterine device, condom with spermicide)&#xD;
&#xD;
          -  Known or suspected active drug or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

